Cargando…
Prospective, randomised, parallel-group, open-label study to evaluate the effectiveness and safety of IMU-838, in combination with oseltamivir, in adults with COVID-19: the IONIC trial protocol
BACKGROUND: Globally, there is a scarcity of effective treatments for SARS-CoV-2 infections (causing COVID-19). Repurposing existing medications may offer the best hope for treating patients with COVID-19 to curb the pandemic. IMU-838 is a dihydroorotate dehydrogenase inhibitor, which is an effectiv...
Autores principales: | Sharma, Kavi, Berry, Lisa, Vryonis, Evangelos, Ali, Asad, Lara, Beatriz, Noufaily, Angela, Parsons, Nicholas, Bradley, Christopher, Haley, Becky, Tabuso, Maria, Arasaradnam, Ramesh P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676417/ https://www.ncbi.nlm.nih.gov/pubmed/36396307 http://dx.doi.org/10.1136/bmjopen-2021-055205 |
Ejemplares similares
-
Trends in Staphylococcus aureus bacteraemia and impacts of infection control practices including universal MRSA admission screening in a hospital in Scotland, 2006–2010: retrospective cohort study and time-series intervention analysis
por: Lawes, Timothy, et al.
Publicado: (2012) -
Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects
por: Muehler, Andreas, et al.
Publicado: (2020) -
Segregation Predicts COVID-19 Fatalities in Less Densely Populated Counties
por: Li, Becky, et al.
Publicado: (2022) -
Protocol for a randomised, single-blind, two-arm, parallel-group controlled trial of the efficacy of rhinothermy delivered by nasal high flow therapy in the treatment of the common cold
por: Bird, Grace, et al.
Publicado: (2019) -
Comparison of standard prophylactic, intermediate prophylactic and therapeutic anticoagulation in patients with severe COVID-19: protocol for the ANTICOVID multicentre, parallel-group, open-label, randomised controlled trial
por: Labbe, Vincent, et al.
Publicado: (2022)